A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Testing the Effectiveness of Immunotherapy Added to a New Drug Combination
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
Testing a New Drug on Advanced Pancreatic Neuroendocrine Tumors
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).
Radiation and Chemotherapy to Make Pancreatic Cancer Surgically Removable
Can a combination of radiation and chemotherapy make pancreatic tumors that are borderline removeable better candidates for surgery? A clinical trial looks at this question.
Helping Some Types of Chemotherapy Penetrate Pancreatic Tumors
A clinical trial looks at the effectiveness of PEGPH20 in helping chemotherapy penetrate the stroma of pancreatic tumors, to make them removable.
Chemoradiation Before Tumor Removal to Lessen Possible Post-Surgical Disease
A clinical trial examines the effectiveness of presurgical chemotherapy and radiation in making cancer-free margins after tumor removal.
Noninvasive Surgery and a New Drug to Stop Pancreatic Tumors
A clinical trial combines irreversible electroporation (IRE) and immunotherapy to see if the duo is effective against locally advanced pancreatic cancer.
Treating Tumors Before Pancreatic Cancer Surgery
Can neoadjuvant treatment such as chemoradiation make pancreatic cancer removal surgery more effective? That is the question asked by this clinical trial.
Testing an Experimental Combination of Drugs
A clinical trial for some cancers including pancreatic cancer tests the effectiveness of a checkpoint inhibitor and an antisense oligonucleotide inhibitor.